Medicare AdvantagePrior AuthMedium impact
Dihydroergotamine Products (Revised)
Humana·Neurology, Pain Management·Medicare Advantage
We identified it
Jul 22, 2026
Summary
Unable to complete analysis. The policy content provided is a summary-only reference with no specific clinical details, effective date, billing codes, or authorization requirements visible. Access to the full policy document at the source URL is required to extract actionable billing guidance.
Action Required
URGENT: Billing team must access the full policy document from https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a5867bc to determine: (1) Specific Dihydroergotamine product codes affected (likely J1110 or similar HCPCS codes), (2) Prior authorization requirements and process, (3) Effective date, (4) Any documentation requirements or clinical criteria. Flag this policy in your tracking system as pending full review. Contact Humana directly if full policy access is restricted. Do not bill Dihydroergotamine products for Medicare Advantage members until prior authorization requirements are confirmed.